BioGX And Bosch Healthcare Solutions Announce Partnership To Develop Infectious Disease Tests For The Vivalytic Platform

Birmingham, AL, and Stuttgart, Germany, May 26, 2020 – BioGX and Bosch Healthcare Solutions have partnered to develop point-of-care infectious disease tests for the Bosch Vivalytic, all-in-one, platform.

Read more

BD, BioGX Announce FDA Emergency Use Authorization For New COVID-19 Diagnostic For Use In U.S.

FRANKLIN LAKES, N.J. and BIRMINGHAM, Ala., April 3, 2020

BD (Becton, Dickinson and Company) a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a new diagnostic test that will enable hospitals to screen for COVID-19 (coronavirus) on site and get results in under three hours. Read more

Becton Dickinson, BioGX Get FDA Emergency Use Authorization For Rapid SARS-CoV-2 Test

Becton Dickinson and BioGX announced Friday that they received Emergency Use Authorization from the US Food and Drug Administration for a hospital SARS-CoV-2 test. Read more

Becton Dickinson, BioGX Partner To Submit COVID-19 Test For US Emergency Use

NEW YORK – Becton Dickinson and BioGX said on Monday that they have submitted a test to detect SARS-CoV-2, the virus that causes COVID-19, that runs on the BD Max system to the US Food and Drug Administration for Emergency Use Authorization. If authorized, the test could potentially increase screening capacity in the US. Read more

BioGX Receives CE-IVD Mark For Enhanced Flu Assay

Amsterdam, The Netherlands, 22 October 2019 – BioGX B.V., the European subsidiary of Birmingham, Alabama based BioGX, announced it has received CE-IVD marking for its new Flu A, Flu B, RSV A/B automated test. The new test significantly enhances the strain coverage and detection sensitivity, and offers testing for a greater variety of specimen types compared to the initially released test. Read more

BioGX Celebrates Success Of Global Partnership Initiative, Announces New Distribution Partnerships In EMEA And Asia-Pacific

Amsterdam, The Netherlands, 01 November 2018 – Amsterdam-based BioGX B.V., a subsidiary of Birmingham, Alabama based molecular diagnostics company BioGX, today announced several new distribution partnerships in the EMEA and Asia-Pacific as it continues to expand its global presence. Read more

BioGX Launches 5 New CE Mark IVD Tests, Expands Number Of Sexual Health Panels

Amsterdam, The Netherlands, 23 October 2018 – BioGX B.V. recently released 5 new sexual health CE Mark IVD tests, expanding BioGX’s CE-IVD menu to a total of 21 multiplex panels, with additional test panels to be released before the end of 2018. Read more

BioGX Launches Six CE-Mark Tests For Meningitis And Antibiotic Resistance

Amsterdam, The Netherlands, 24 May 2018 – BioGX B.V. continues its *BD MAX menu expansion with the launch of six additional CE-Mark infectious disease tests on Becton, Dickinson and Company’s BD MAX Sample-to-Answer platform. This brings the company’s CE-Mark menu for the BD MAX to eleven tests, with an additional ten planned for the second half of 2018. Read more

BioGX And Launch Diagnostics Announce Distribution Partnership For U.K. And Ireland

BIRMINGHAM, Ala., Feb. 8, 2018 /PRNewswire/ — BioGX continues to expand its global presence with the announcement of a distribution partnership between BioGX’s Amsterdam-based European subsidiary, BioGX B.V., and U.K.-based distributor, Launch Diagnostics. Read more

BioGX BV And AxonLab AG Announce Distribution Partnership

BIRMINGHAM, Ala., Feb. 6, 2018 /PRNewswire/ — BioGX continues to expand its international presence with the announcement of a new strategic partnership between BioGX’s Amsterdam-based European subsidiary and Switzerland-based distributor, AxonLab AG. Read more